Funded Biotechnology Startups in United States
Among the 50 most recent disclosed biotechnology rounds shown here, the largest disclosed amount is Definium Therapeutics’ $805M round dated 2026-06-23, dw…
Among the 50 most recent disclosed biotechnology rounds shown here, the largest disclosed amount is Definium Therapeutics’ $805M round dated 2026-06-23, dwarfing the next-highest disclosed amounts such as Ligand Pharmaceuticals at $625M (2026-06-23) and Nuvation Bio at $250M (2026-06-25). The disclosed floor in this slice is Andon Bio’s $250K (Seed, 2026-06-29), with multiple small-ticket rounds clustered near $2M–$4M (e.g., Aptevo Therapeutics $2M on 2026-06-30; Oligomerix $2M on 2026-06-17).
The time window is tightly concentrated: every row falls between 2026-06-17 and 2026-06-30, and multiple large rounds land on the same dates (notably 2026-06-23, which includes Definium Therapeutics $805M; Ligand Pharmaceuticals $625M; Osanni Bio $190M; and Cour Pharmaceuticals Development $50M). Geographically, the list clusters heavily around Massachusetts locations (Boston appears with Beeline Medicines $126M on 2026-06-30, Pyxis Oncology $50M on 2026-06-30, and Anodyne Nanotech $13M on 2026-06-24; Cambridge appears with Flare Therapeutics $85M on 2026-06-30, Decoy Therapeutics $4M on 2026-06-26, and TRIMTECH Therapeutics $14M on 2026-06-23). Stage labeling is mixed, with “Series Unknown” and “undisclosed” amounts both present across the date window (36 “Series Unknown” rows; 4 “undisclosed” rows).
Most recent rounds
50 of 2,5062,456 more funded startups
This page shows the 50 most recent rounds (back to Jun 2026). The full 2,506-company history for this listing is available on a paid plan.
Unlock all 2,506 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which disclosed round is the clear outlier, and how much larger is it than the rest of the list?
Definium Therapeutics’ $805M (2026-06-23) is the only disclosed deal in the $500M+ range, with Ligand Pharmaceuticals the next-largest disclosed amount at $625M (2026-06-23). Everything else is substantially below those figures, including Nuvation Bio’s $250M (2026-06-25).
Do the most recent rounds cluster in a narrow date window or spread across time?
They’re concentrated tightly: the earliest round date shown is 2026-06-17 and the latest is 2026-06-30. Several high-profile financings cluster on 2026-06-23, including Definium Therapeutics $805M, Ligand Pharmaceuticals $625M, Osanni Bio $190M, and Cour Pharmaceuticals Development $50M.
Are any cities or states over-represented in these 50 entries?
Massachusetts shows up repeatedly, especially around Boston/Cambridge. Boston-based entries include Beeline Medicines ($126M, 2026-06-30), Pyxis Oncology ($50M, 2026-06-30), and NorthLinks Bio ($34M, 2026-06-23), while Cambridge appears with Flare Therapeutics ($85M, 2026-06-30) and Decoy Therapeutics ($4M, 2026-06-26).
What’s the stage mix in this slice—does “Series Unknown” dominate?
Yes. “Series Unknown” appears in 36 of the 50 rows, while “undisclosed” amounts occur in 4 rows (e.g., Optimeos Life Sciences, ARMR Sciences, and MannKind). Named stages visible elsewhere include Seed (e.g., Andon Bio $250K on 2026-06-29) and larger labeled rounds like Series C (Flare Therapeutics $85M on 2026-06-30).
How extreme are the small-ticket rounds compared with the disclosed high end?
The smallest disclosed amount is Andon Bio’s $250K (Seed, 2026-06-29), and multiple other disclosed deals sit in the low single-digit millions (e.g., Aptevo Therapeutics $2M on 2026-06-30; Cadrenal Therapeutics $3M on 2026-06-30; Oligomerix $2M on 2026-06-17). That means the disclosed range spans from $250K to $805M within this 2026-06-17 to 2026-06-30 window.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.